

Drug Name: Oxervate (Cenegermin-bkbj)

Date: 5/2019, 5/2020

Drug Name:	Oxervate (Cenegermin-bkbj)
Required Medical	The patient must meet all of the following:
Information:	 The patient must experience persistent epithelial defects (PED) or corneal ulceration of at least 2 weeks duration refractory to one or more conventional non-surgical treatments (e.g., preservative free artificial tears). Evidence of decreased corneal sensitivity (less than or equal to 4 cm
	using the Cochet-Bonnet aesthesiometer) within the area of the PED or corneal ulcer and outside of the area of the defect in at least one corneal quadrant.
	 Performance of Schirmer test without anesthesia resulting in greater than 3 mm of moisture in 5 minutes
	O The patient has not received a previous course of Oxervate in the affected eye.
	o The patient is 2 years of age or older
	 Prescribed by an ophthalmologist
	 The patient is counseled on proper technique
	 Provider confirms that member/caregiver has sufficient dexterity to perform administration
Note(s):	Quantity Limit: 28 vials every 28 days (If a second eye is affected, QL of 56 vials per 28 days)
Coverage Duration:	8 weeks